San Francisco, CANCT07226895Now EnrollingIRB Ready

Clinical High Risk for Psychosis (CHR) Clinical Trial in San Francisco, CA

Access cutting-edge clinical high risk for psychosis (chr) treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.

Sponsored by Monument Therapeutics Limited

Quick Self-Assessment

See if you qualify for this San Francisco location

Preparing your pre-screening questions…

Expert Care in San Francisco

Access clinical high risk for psychosis (chr) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related clinical high risk for psychosis (chr) treatment provided free

Apply for This San Francisco Location

Check if you qualify for this clinical high risk for psychosis (chr) clinical trial in San Francisco, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Francisco

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Francisco site if eligible
  4. 4Begin participation

About This Clinical High Risk for Psychosis (CHR) Study in San Francisco

The goal of this clinical trial is to learn how tests undertaken by people at high risk of developing psychosis (aged 17 to 30 years old) change when those people are given the study drug MT1988 daily for 8 weeks. This will help identify tests that could be used in later trials developing treatments for symptoms in people at high risk of developing psychosis, to measure whether those new treatments are effective. The main question this trial aims to answer is: Can any of the tests (biomarkers) used in this study detect changes in participants dosed with one of two different dose levels of MT1988? Researchers will compare the results from two dose levels of MT1988 to a placebo group. Researchers do not expect to see the test results change in participants taking placebo and this will be compared to changes expected in test results in participants taking MT1988. Participants will: * take a dose of MT1988 or placebo twice per day for 8 weeks * attend clinic appointments every two weeks to undertake assessments * report any side effects they experience to the researchers

Sponsor: Monument Therapeutics Limited

Who Can Participate

Inclusion Criteria

Aged 17 to 30 years at time of consent.
Capacity to provide informed consent. (For patients under 17 years, participants must assent and informed consent provided by one parent or legal guardian).
Meet diagnostic criteria for Clinical High Risk of Psychosis (CHR).
For females of reproductive potential - not pregnant or nursing and willing to comply with contraceptive requirements.

Exclusion Criteria

Clinically significant medical disorder or laboratory test abnormality at Day 1.
History of or current condition which may prevent participant from complying with study procedures.
Past or current schizophrenia, other disorder with symptoms of psychosis, major cognitive disorder resulting from traumatic brain injury.
Received antipsychotic medication equivalent to a total lifetime haloperidol dose \>50 mg.
Current use of medications which could interfere with the study endpoints - to be assessed by the Investigator at screening.
Unable to abstain from nicotine (e.g. cigarettes, vape) for two hours before cognitive testing.
Unable to abstain from marijuana use on test day prior to test completion.
History of suicide attempt or behavior in previous 12 months, or risk of suicidal behavior during the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT07226895) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Clinical High Risk for Psychosis (CHR) Treatment Options in San Francisco, CA

If you're searching for clinical high risk for psychosis (chr) treatment options in San Francisco, CA, this clinical trial (NCT07226895) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced clinical high risk for psychosis (chr) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all clinical high risk for psychosis (chr) clinical trials near you to find additional studies recruiting in your area.

More Schizophrenia Trials in San Francisco, CA

See all schizophrenia clinical trials recruiting in San Francisco — not just this study.

Browse Schizophrenia Trials in San Francisco

Ready to Join in San Francisco?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Francisco, CA